ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 132 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.88 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $2,524,000 | +25.9% | 75,357 | 0.0% | 0.02% | +38.9% |
| Q3 2016 | $2,005,000 | +20.6% | 75,357 | 0.0% | 0.02% | +5.9% |
| Q2 2016 | $1,662,000 | -24.9% | 75,357 | 0.0% | 0.02% | -26.1% |
| Q1 2016 | $2,213,000 | -11.1% | 75,357 | 0.0% | 0.02% | +9.5% |
| Q4 2015 | $2,488,000 | -8.6% | 75,357 | 0.0% | 0.02% | -16.0% |
| Q3 2015 | $2,723,000 | -19.7% | 75,357 | 0.0% | 0.02% | -16.7% |
| Q2 2015 | $3,390,000 | +46.9% | 75,357 | 0.0% | 0.03% | +57.9% |
| Q1 2015 | $2,307,000 | -39.8% | 75,357 | 0.0% | 0.02% | -51.3% |
| Q4 2014 | $3,832,000 | +28.5% | 75,357 | 0.0% | 0.04% | +2.6% |
| Q3 2014 | $2,982,000 | -8.1% | 75,357 | 0.0% | 0.04% | -5.0% |
| Q2 2014 | $3,246,000 | +0.3% | 75,357 | -6.9% | 0.04% | -2.4% |
| Q1 2014 | $3,237,000 | +8.8% | 80,957 | -25.8% | 0.04% | -2.4% |
| Q4 2013 | $2,976,000 | +3.9% | 109,097 | -12.7% | 0.04% | +2.4% |
| Q3 2013 | $2,865,000 | +29.4% | 125,000 | 0.0% | 0.04% | -6.8% |
| Q2 2013 | $2,214,000 | – | 125,000 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 476,042 | $45,472,000 | 12.29% |
| Stonepine Capital Management, LLC | 60,840 | $5,811,000 | 3.34% |
| ACUTA CAPITAL PARTNERS, LLC | 61,000 | $5,827,000 | 2.77% |
| Virtus ETF Advisers LLC | 10,634 | $1,016,000 | 2.16% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 61,000 | $5,827,000 | 2.15% |
| ARMISTICE CAPITAL, LLC | 372,000 | $35,533,000 | 1.94% |
| Matarin Capital Management, LLC | 209,403 | $20,002,000 | 1.46% |
| Monashee Investment Management LLC | 50,000 | $4,776,000 | 1.10% |
| Granahan Investment Management | 151,322 | $14,454,000 | 0.78% |
| ALGERT GLOBAL LLC | 13,186 | $1,260,000 | 0.72% |